Replies to post #139482 on Biotech Values

[TastyTheElf]

iwfal, do you think any time soon we're going to reach that point where, by sheer brute repetition, you'll be able to declare: Well, I think I've made my argument.

The horse is dead, all the flesh has been flayed from every quarter, the flies have finished up and are all gone, and the bones are now loose and scattered.

You've run your 5kb Excel spreadsheet that takes 4 parameters and you've figured out the next local maxima for sunspots and typhoons in Malaysia. We get it. Thanks.

[biomaven0]

As I noted on the other board - of 11 Big Pharma onc trials I hunted down, with absolutely no ambiguity in the protocol, 5 had interims, and 2 of those 5 used an interim that, had they stopped at the interim, would have been far from spectacular.

I think the recent ridaforolimus briefing docs indicated that technically they could have stopped at the 2nd interim but the DSMB elected not to. Paradoxically, the advantage of rida over the other arm at that point was 7 weeks - likely enough for approval.

Peter